JP2009521206A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009521206A5 JP2009521206A5 JP2008508006A JP2008508006A JP2009521206A5 JP 2009521206 A5 JP2009521206 A5 JP 2009521206A5 JP 2008508006 A JP2008508006 A JP 2008508006A JP 2008508006 A JP2008508006 A JP 2008508006A JP 2009521206 A5 JP2009521206 A5 JP 2009521206A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- present
- further embodiment
- receptor alpha
- folate receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000010451 Folate receptor alpha Human genes 0.000 claims description 28
- 108050001931 Folate receptor alpha Proteins 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 36
- 238000000034 method Methods 0.000 description 35
- 239000000126 substance Substances 0.000 description 16
- 230000000973 chemotherapeutic effect Effects 0.000 description 13
- 239000002157 polynucleotide Substances 0.000 description 11
- 102000040430 polynucleotide Human genes 0.000 description 11
- 108091033319 polynucleotide Proteins 0.000 description 11
- 230000003432 anti-folate effect Effects 0.000 description 10
- 229940127074 antifolate Drugs 0.000 description 10
- 239000004052 folic acid antagonist Substances 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 230000012010 growth Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000012642 immune effector Substances 0.000 description 6
- 229940121354 immunomodulator Drugs 0.000 description 6
- 239000000032 diagnostic agent Substances 0.000 description 4
- 229940039227 diagnostic agent Drugs 0.000 description 4
- 102000006815 folate receptor Human genes 0.000 description 4
- 108020005243 folate receptor Proteins 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67418505P | 2005-04-22 | 2005-04-22 | |
| PCT/US2006/016004 WO2006116592A2 (en) | 2005-04-22 | 2006-04-24 | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011290406A Division JP2012100675A (ja) | 2005-04-22 | 2011-12-29 | 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009521206A JP2009521206A (ja) | 2009-06-04 |
| JP2009521206A5 true JP2009521206A5 (https=) | 2011-09-01 |
Family
ID=37215502
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008508006A Pending JP2009521206A (ja) | 2005-04-22 | 2006-04-24 | 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体 |
| JP2011290406A Pending JP2012100675A (ja) | 2005-04-22 | 2011-12-29 | 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011290406A Pending JP2012100675A (ja) | 2005-04-22 | 2011-12-29 | 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US20060239910A1 (https=) |
| EP (2) | EP2172487A1 (https=) |
| JP (2) | JP2009521206A (https=) |
| AU (1) | AU2006241099B2 (https=) |
| CA (1) | CA2607444C (https=) |
| WO (1) | WO2006116592A2 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004249673A1 (en) * | 2003-05-23 | 2004-12-29 | Morphotek, Inc. | Anti alpha - folate - receptor - tetramer antibodies |
| AU2004261229A1 (en) * | 2003-07-29 | 2005-02-10 | Eisai, Inc. | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
| CA2556027C (en) | 2004-02-12 | 2015-11-24 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| CA2600505C (en) | 2005-03-10 | 2016-05-03 | Morphotek, Inc. | Anti-mesothelin antibodies |
| EP2172487A1 (en) | 2005-04-22 | 2010-04-07 | Morphotek Inc. | Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells |
| US20090191202A1 (en) * | 2005-09-29 | 2009-07-30 | Jamieson Catriona Helen M | Methods for manipulating phagocytosis mediated by CD47 |
| AU2009205665B2 (en) | 2008-01-15 | 2013-12-05 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for manipulating phagocytosis mediated by CD47 |
| CA2965198C (en) | 2008-01-15 | 2021-02-16 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| US11072655B2 (en) | 2008-01-15 | 2021-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| AU2014203172B2 (en) * | 2010-02-24 | 2016-03-10 | Immunogen, Inc. | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof |
| CN103037900B (zh) * | 2010-02-24 | 2016-04-06 | 伊缪诺金公司 | 叶酸受体1抗体与免疫缀合物以及其用途 |
| HRP20221260T1 (hr) | 2010-05-14 | 2023-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Humanizirana i kimerna monoklonska protutijela za cd47 |
| US20120164137A1 (en) * | 2010-10-20 | 2012-06-28 | Morphotek, Inc. | Anti-folate receptor alpha antibody glycoforms |
| AU2011323124C1 (en) * | 2010-11-05 | 2016-09-22 | Eisai Inc. | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
| US9402865B2 (en) * | 2011-01-18 | 2016-08-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| US20140010756A1 (en) | 2011-03-18 | 2014-01-09 | Kagoshima University | Composition for treatment and diagnosis of pancreatic cancer |
| IL281714B2 (en) * | 2011-04-01 | 2023-11-01 | Immunogen Inc | Methods for increasing the effectiveness of FOLR1 cancer therapy |
| PL2731972T3 (pl) * | 2011-07-15 | 2018-06-29 | Eisai R&D Management Co., Ltd. | Przeciwciała skierowane przeciwko receptorowi folianowemu alfa i ich zastosowania |
| HUE049693T2 (hu) * | 2012-08-31 | 2020-10-28 | Immunogen Inc | Diagnosztikai ASSAY-k és készletek a folát receptor 1 kimutatására |
| US9598489B2 (en) | 2012-10-05 | 2017-03-21 | The Trustees Of The Univeristy Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
| JP6224619B2 (ja) * | 2012-12-07 | 2017-11-01 | 協和発酵キリン株式会社 | 抗ｆｏｌｒ１抗体 |
| JP6383787B2 (ja) | 2013-06-20 | 2018-08-29 | モルフォテック， インコーポレイテッド | 卵巣癌の治療方法 |
| AU2014312086B2 (en) | 2013-08-30 | 2020-03-12 | Immunogen, Inc. | Antibodies and assays for detection of folate receptor 1 |
| DK3221355T3 (da) | 2014-11-20 | 2020-12-07 | Hoffmann La Roche | Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister |
| RS61010B1 (sr) | 2014-11-20 | 2020-11-30 | Hoffmann La Roche | Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3 |
| SI3221357T1 (sl) | 2014-11-20 | 2020-09-30 | F. Hoffmann-La Roche Ag | Pogoste lahke verige in načini uporabe |
| CN107624071A (zh) | 2015-04-17 | 2018-01-23 | 诺福泰克公司 | 肺癌治疗方法 |
| AU2016323968B2 (en) | 2015-09-17 | 2023-07-06 | Immunogen, Inc. | Therapeutic combinations comprising anti-FOLR1 immunoconjugates |
| NZ741324A (en) | 2015-09-21 | 2021-09-24 | Erasmus Univ Medical Center | Anti-cd47 antibodies and methods of use |
| CN115925952A (zh) | 2018-03-13 | 2023-04-07 | 东莞凡恩世生物医药有限公司 | 抗叶酸受体1抗体及其用途 |
| KR102275930B1 (ko) | 2018-03-14 | 2021-07-12 | (주)알테오젠 | Folr1에 특이적으로 결합하는 항체 및 그의 용도 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020129838A1 (ja) * | 2018-12-17 | 2020-06-25 | 株式会社カネカ | 特定抗原特異的抗体を産生する細胞のスクリーニング方法 |
| WO2020223221A1 (en) | 2019-04-29 | 2020-11-05 | Immunogen, Inc. | Biparatopic fr-alpha antibodies and immunoconjugates |
| WO2024104431A1 (zh) * | 2022-11-16 | 2024-05-23 | 迈威(上海)生物科技股份有限公司 | 一种靶向FRα的抗体或其抗原结合片段及其应用 |
| US12600795B2 (en) | 2023-12-26 | 2026-04-14 | Medicovestor, Inc. | Oligomeric IgG for immunotherapeutics and diagnostics |
| US12378314B1 (en) * | 2024-02-02 | 2025-08-05 | Medicovestor, Inc. | Proteins that bind folate receptor alpha including fully-human antibodies |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4694778A (en) * | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| US4851332A (en) | 1985-04-01 | 1989-07-25 | Sloan-Kettering Institute For Cancer Research | Choriocarcinoma monoclonal antibodies and antibody panels |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5006470A (en) | 1987-04-16 | 1991-04-09 | Sloan-Kettering Institute For Cancer Research | Human monoclonal antibodies to cell surface antigens of melanoma |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5688488A (en) | 1989-04-03 | 1997-11-18 | Purdue Research Foundation | Composition and method for tumor imaging |
| US5789650A (en) * | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP0554356B1 (en) * | 1990-10-12 | 1998-09-16 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | A monoclonal antibody |
| US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US5646253A (en) * | 1994-03-08 | 1997-07-08 | Memorial Sloan-Kettering Cancer Center | Recombinant human anti-LK26 antibodies |
| US6191268B1 (en) * | 1993-12-17 | 2001-02-20 | Dana-Farber Cancer Institute | Compositions and methods relating to DNA mismatch repair genes |
| NZ281023A (en) * | 1994-01-27 | 1998-04-27 | Human Genome Sciences Inc | Human dna mismatch repair proteins and coding sequences |
| DE19513676A1 (de) * | 1995-04-11 | 1996-10-17 | Behringwerke Ag | Cytoplasmatische Expression von Antikörpern, Antikörperfragmenten und Antikörperfragmentfusionsmolekülen in E.coli |
| DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
| DE69726404T2 (de) | 1996-01-05 | 2004-09-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mesothelinantigen, verfahren und testsatz zur targetierung |
| SK150298A3 (en) | 1996-05-04 | 1999-04-13 | Zeneca Ltd | Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system |
| US6809184B1 (en) * | 1997-12-01 | 2004-10-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
| US6146894A (en) | 1998-04-14 | 2000-11-14 | The Johns Hopkins University | Method for generating hypermutable organisms |
| US6365410B1 (en) * | 1999-05-19 | 2002-04-02 | Genencor International, Inc. | Directed evolution of microorganisms |
| DK1180123T3 (da) * | 1999-05-27 | 2008-10-13 | Us Gov Health & Human Serv | Immunkonjugater, der har höj bindingsaffinitet |
| ATE423467T1 (de) | 2000-11-07 | 2009-03-15 | Morphotek Inc | Verfahren zur herstellung von genetisch modifizierten antikörperproduzierenden zelllinien mit verbesserten antikörpereigenschaften |
| US6808894B1 (en) * | 2000-11-07 | 2004-10-26 | Morphotek, Inc. | Methods for generating genetically altered antibody producing cell lines with improved antibody characteristics |
| ATE501635T1 (de) | 2001-01-15 | 2011-04-15 | Morphotek Inc | Chemische hemmstoffe des mismatch-repair |
| CA2445826C (en) | 2001-05-02 | 2014-03-25 | Purdue Research Foundation | Treatment and diagnosis of macrophage mediated disease |
| EP1258255A1 (en) | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
| CA2443437A1 (en) | 2001-05-18 | 2002-11-28 | Boehringer Ingelheim International Gmbh | Antibodies specific for cd44v6 |
| GB2403222A (en) | 2002-04-01 | 2004-12-29 | Utah Ventures Ii L P | Tissue-specific endothelial membrane proteins |
| US20040115695A1 (en) | 2002-07-19 | 2004-06-17 | Morphotek Inc. | Methods for generating enhanced antibody producing cell lines with improved growth characteristics |
| AU2004249673A1 (en) * | 2003-05-23 | 2004-12-29 | Morphotek, Inc. | Anti alpha - folate - receptor - tetramer antibodies |
| AU2004261229A1 (en) | 2003-07-29 | 2005-02-10 | Eisai, Inc. | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
| JP2007525971A (ja) | 2003-08-05 | 2007-09-13 | モルフォテック、インク． | 癌に関連する変異体細胞表面分子 |
| CA2556027C (en) * | 2004-02-12 | 2015-11-24 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| EA200700751A1 (ru) | 2004-10-05 | 2008-06-30 | Элан Фарма Интернэшнл Лимитед | Способы и композиции для улучшения продуцирования рекомбинантного белка |
| CA2600505C (en) * | 2005-03-10 | 2016-05-03 | Morphotek, Inc. | Anti-mesothelin antibodies |
| ATE460668T1 (de) | 2005-03-30 | 2010-03-15 | Purdue Research Foundation | Verfahren zur prognose von brustkrebs mittels quantifizierung von zellulären folat vitamin rezeptoren |
| EP2172487A1 (en) * | 2005-04-22 | 2010-04-07 | Morphotek Inc. | Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells |
| US8795633B2 (en) | 2005-09-23 | 2014-08-05 | Purdue Research Foundation | Multiphoton in vivo flow cytometry method and device |
| US20070161018A1 (en) | 2005-11-04 | 2007-07-12 | Johji Inazawa | Method for detecting cancer and a method for suppressing cancer |
| EP1900752A1 (en) | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
| JP2010509570A (ja) | 2006-11-03 | 2010-03-25 | パーデュー・リサーチ・ファウンデーション | エクスビボフローサイトメトリーの方法および装置 |
| BRPI0812970A2 (pt) | 2007-06-25 | 2019-09-24 | Endocyte Inc | conjugados contendo espaçadores hidrofílicos |
| WO2009032974A2 (en) | 2007-09-06 | 2009-03-12 | Tripath Imaging, Inc. | Nucleic acid-based methods for the detection of ovarian cancer |
| GB0725077D0 (en) | 2007-12-21 | 2008-01-30 | Univ Murcia | Antifolate com[ounds for the treatment of melanoma |
| WO2009132081A2 (en) | 2008-04-24 | 2009-10-29 | The Research Foundation Of State University Of New York | Monoclonal antibody-based targeting of folate receptors |
| US20120164137A1 (en) * | 2010-10-20 | 2012-06-28 | Morphotek, Inc. | Anti-folate receptor alpha antibody glycoforms |
| AU2011323124C1 (en) * | 2010-11-05 | 2016-09-22 | Eisai Inc. | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
| US9512223B2 (en) * | 2012-05-15 | 2016-12-06 | Morphotek, Inc. | Methods for treatment of gastric cancer |
| JP6224619B2 (ja) * | 2012-12-07 | 2017-11-01 | 協和発酵キリン株式会社 | 抗ｆｏｌｒ１抗体 |
| JP6383787B2 (ja) * | 2013-06-20 | 2018-08-29 | モルフォテック， インコーポレイテッド | 卵巣癌の治療方法 |
| CN107624071A (zh) * | 2015-04-17 | 2018-01-23 | 诺福泰克公司 | 肺癌治疗方法 |
| EP3423105B1 (en) * | 2016-03-02 | 2021-05-05 | Eisai R&D Management Co., Ltd. | Eribulin-based antibody-drug conjugates and methods of use |
-
2006
- 2006-04-24 EP EP20090176155 patent/EP2172487A1/en not_active Withdrawn
- 2006-04-24 JP JP2008508006A patent/JP2009521206A/ja active Pending
- 2006-04-24 EP EP06758662A patent/EP1879922A2/en not_active Withdrawn
- 2006-04-24 CA CA2607444A patent/CA2607444C/en not_active Expired - Lifetime
- 2006-04-24 US US11/410,442 patent/US20060239910A1/en not_active Abandoned
- 2006-04-24 WO PCT/US2006/016004 patent/WO2006116592A2/en not_active Ceased
- 2006-04-24 AU AU2006241099A patent/AU2006241099B2/en not_active Expired
-
2009
- 2009-07-16 US US12/503,983 patent/US8124083B2/en active Active
-
2011
- 2011-12-29 JP JP2011290406A patent/JP2012100675A/ja active Pending
-
2012
- 2012-01-24 US US13/356,724 patent/US9144614B2/en active Active
-
2015
- 2015-07-27 US US14/809,887 patent/US9522195B2/en not_active Expired - Lifetime
-
2016
- 2016-11-08 US US15/346,332 patent/US10253106B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009521206A5 (https=) | ||
| JP2012100675A5 (https=) | ||
| US20240052063A1 (en) | Binding Proteins 2 | |
| ES2719495T5 (en) | Anti-b7-h6 antibody, fusion proteins, and methods of using the same | |
| AU2018250312C1 (en) | Bioorthogonal compositions | |
| EP2513146B1 (en) | Antibodies against ror1 capable of inducing cell death of cll | |
| CN109661400A (zh) | 用于耗尽cd117+细胞的组合物和方法 | |
| KR102414718B1 (ko) | 암의 진단 및 치료를 위한 조성물 및 방법 | |
| JP2016509582A5 (https=) | ||
| EP3448987A2 (en) | Compositions for the treatment of disease | |
| CA2925915C (en) | Anti-epcam antibodies and methods of use | |
| JP2012100676A5 (https=) | ||
| JP2012100677A5 (https=) | ||
| JP2012521217A5 (https=) | ||
| JP2013518912A5 (https=) | ||
| KR20160006697A (ko) | 간세포 암종을 검출 및 치료하기 위한 조성물 및 방법 | |
| US11666664B2 (en) | Self assembling molecules for targeted drug delivery | |
| JP2022513421A5 (https=) | ||
| JP2014500862A5 (https=) | ||
| JP6814824B2 (ja) | アポトーシスを誘導するための組成物及び方法 | |
| JP2014515600A5 (https=) | ||
| TW201905000A (zh) | 含有抗globo h抗體之抗體－藥物共軛物及其用途 | |
| CN115279789A (zh) | 破坏gal3和胰岛素受体或整联蛋白的相互作用的抗体及其使用方法 | |
| KR20140090295A (ko) | T 세포 특이적인 인간화 단일조각항체 전달체 | |
| Byun et al. | Preclinical Proof of Concept for the Single‐Protein Anticancer Molecule Targeting Both a Tumor Surface Antigen and an Intracellular Oncoprotein |